This page lists all known medications that could potentially lead to 'Hyperkalaemia' as a side effect. It's important to note that mild side effects are quite common with medications. The medication(s ...

Hyperkalaemia, characterised by elevated potassium levels, affects 6-7% of the global population, posing severe risks to those with chronic kidney disease. Key symptoms include shortness of breath, ...

Preliminary guidelines released by the National Institute for Health and Care Excellence do not recommend NHS funding for hyperkalaemia treatments Lokelma and Veltassa. Preliminary guidelines released ...

AstraZeneca’s hyperkalaemia treatment Lokelma has been approved in Europe, a relief to the company after two years of delay to the potential blockbuster. Formerly known as ZS-9, Lokelma (sodium ...

The appraisal committee considered evidence submitted by Vifor Pharma and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.

In patients with type 2 diabetes mellitus (T2DM), the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly reduced the risk of developing a hyperkalaemia event but did not reduce ...

AstraZeneca’s Lokelma has been approved in Europe to treat hyperkalaemia in adult patients. AstraZeneca’s Lokelma has been approved in Europe to treat hyperkalaemia in adult patients. Hyperkalaemia is ...

AstraZeneca PLC AZN announced that the Japanese regulatory authority has granted marketing approval to Lokelma (sodium zirconium cyclosilicate) for the treatment of patients with hyperkalaemia in ...

AstraZeneca’s hyperkalaemia therapy Lokelma has picked up a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP), bringing it one step closer to European licensing. It ...

The appraisal committee considered evidence submitted by AstraZeneca and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.

AstraZeneca PLC AZN announced that the Japanese regulatory authority has granted marketing approval to Lokelma (sodium zirconium cyclosilicate) for the treatment of patients with hyperkalaemia in ...